Evolus, a performance beauty company focused on aesthetics, has launched operations in Australia by introducing Nuceiva (prabotulinumtoxinA). This marks a significant expansion of their global presence.
The Therapeutic Goods Administration approves Nuceiva for improving the appearance of moderate to severe frown lines in adults. It has been the fastest-growing neurotoxin in the United States for three years.
Evolus has established a direct operating entity in Australia led by Daniel Henry. By collaborating with healthcare professionals, they aim to provide Nuceiva to patients seeking non-surgical rejuvenation options.
The Australian expansion highlights the company’s commitment to strategic growth and customer focus. This move strengthens their leadership position in the global aesthetics industry.
A comprehensive clinical program backs Nuceiva’s safety and efficacy. Three Phase III trials and two long-term safety studies have demonstrated its effectiveness and a side effect profile consistent with other neurotoxins in this class.
Leading plastic surgeon Dr. Steven Liew expressed his enthusiasm for collaborating with Evolus. “I believe Nuceiva will provide healthcare professionals with more choices, allowing them to meet the evolving beauty preferences and needs of patients.”
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
